EC approval for Ontozry
Angelini Pharma has announced European Commission (EC) approval for anti-seizure drug Ontozry (cenobamate).
The move allows doctors to prescribe the drug for the adjunctive treatment of focal-onset seizures with or without secondary generalisation in adults who have not been adequately controlled despite a history of treatment with at least two anti-epileptic medicines.
The EC marketing authorisation is valid in all European Union (EU) member states plus Iceland, Norway and Liechtenstein; the UK s Medicines and Healthcare Regulatory Agency (MHRA) is currently reviewing the submission for the drug via the reliance route .
People with epilepsy whose seizures are poorly controlled have “higher morbidity and mortality rates and often experience comorbid illnesses, social stigmatisation and an impaired quality of life,” the company notes, highlighting the existing unmet need for such patients.
SK Biopharm s epilepsy drug cleared for sale in Europe
pulsenews.co.kr - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pulsenews.co.kr Daily Mail and Mail on Sunday newspapers.
ONTOZRY® (Cenobamate) Receives European Commission Approval for the Treatment of Drug-Resistant Focal-Onset Seizures in Adults
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
(1)
Centessa Pharmaceuticals ( Centessa ), a pharmaceutical company consisting of 10 subsidiary companies advancing a portfolio of high conviction programs with strong biological validation, today announced key additions to its leadership team. Gregory Weinhoff, M.D., MBA, joined the team as chief financial officer, while Mary Lynne Hedley, Ph.D., Robert M. Califf, M.D., MACC, and Samarth Kulkarni, Ph.D., joined Centessa s board of directors effective February 23, 2021. Centessa launched last month with a goal of redefining pharmaceutical R&D productivity through an asset-centric model that we believe has the potential to support the advancement of novel programs by industry-leading experts in their respective fields, said Saurabh Saha, M.D., Ph.D., chief executive officer of Centessa. Each member of our team brings industry-leading qualifications and differentiated perspectives to help guide the expansion of our organization. We are thrilled to welcome Greg, Mary Lynne, Robert